Correlation Engine 2.0
Clear Search sequence regions


  • adenocarcinoma (1)
  • adenoid (1)
  • adenoid cystic carcinomas (1)
  • adenoma (2)
  • CIC (1)
  • ERBB2 (1)
  • FGFR2 (1)
  • gene (1)
  • gene fusion (1)
  • humans (1)
  • MYB (3)
  • MYBL1 (2)
  • NFIB (3)
  • NOTCH1 (1)
  • poor prognosis (1)
  • rna (1)
  • THSD7B (1)
  • TP53 (1)
  • Sizes of these terms reflect their relevance to your search.

    Malignant tumours of the lacrimal apparatus are rare and frequently show a poor prognosis, with no clear therapeutic standards. Characterisation of the genetic landscape of these rare tumours is sparse, and therefore therapeutics generally follow those of their common salivary gland counterparts. To further clarify the pathophysiology and discover potential therapeutic targets, we investigated the genetic landscape of eight tumours of the lacrimal apparatus. DNA and RNA sequencing were performed to identify genetic mutations and gene fusions. Immunohistochemistry, fluorescence in-situ hybridisation and reverse transcription-polymerase chain reaction followed by Sanger sequencing were performed to confirm the identified molecular alterations. Genetic alterations were detected in six tumours. Among five adenoid cystic carcinomas (ACC), four had confirmed alterations of MYB or MYBL1 genes, including a MYB::NFIB fusion, a MYBL1::NFIB fusion, a MYB amplification and a novel NFIB::THSD7B fusion. Mutations in genes encoding epigenetic modifiers, as well as NOTCH1, FGFR2 and ATM mutations, were also identified in ACCs. A carcinoma ex pleomorphic adenoma showed TP53 and CIC mutations and an amplification of ERBB2. A transitional cell carcinoma was associated with HPV16 infection. No genetic alteration was found for one adenocarcinoma, not otherwise specified. Our study highlights the variety of molecular alterations associated with lacrimal system tumours and emphasises the importance of molecular testing in these tumours, which can reveal potentially targetable mutations. Our results also reinforce the hypothesis of a common physiopathology of all ACCs, regardless of their primary location. © 2023 John Wiley & Sons Ltd.

    Citation

    Roseline Vibert, Joanna Cyrta, Elodie Girard, Sophie Vacher, Célia Dupain, Samantha Antonio, Jennifer Wong, Sylvain Baulande, Juliana Monteiro Ferras De Sousa, Anne Vincent-Salomon, Julien Masliah-Planchon, Nicolas Girard, Christophe Le Tourneau, Maud Kamal, Ivan Bièche. Molecular characterisation of tumours of the lacrimal apparatus. Histopathology. 2023 Dec;83(6):925-935

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 37706251

    View Full Text